Dose finding for new vaccines: the role for
  immunostimulation/immunodynamic modelling by Rhodes, Sophie J. et al.
Dose finding for new vaccines: the role for 
immunostimulation/immunodynamic modelling 
 
Authors: Sophie J. Rhodesa*, Gwenan M. Knighta, Denise E. Kirschnerb, Richard G. Whitea+, 
Thomas G. Evansc+ 
 
* Corresponding author 
+ joint senior authors 
 
Institutions:  
a TB Modelling Group, CMMID, TB Centre, London School of Hygiene and Tropical Medicine, 
UK 
b University of Michigan Medical School, Ann Arbor, MI, USA 
c Vaccitech, Oxford, UK 
  
Abstract 
 
Current methods to optimize vaccine dose are purely empirically based, whereas in the drug 
development field, dosing determinations use far more advanced quantitative methodology 
to accelerate decision-making. Applying these established methods in the field of vaccine 
development may reduce the currently large clinical trial sample sizes, long time frames, high 
costs, and ultimately have a better potential to save lives. We propose the field of 
immunostimulation/immunodynamic (IS/ID) modelling, which aims to translate 
mathematical frameworks used for drug dosing towards optimizing vaccine dose decision-
making. Analogous to PK/PD modelling, IS/ID modelling approaches apply mathematical 
models to describe the underlying mechanisms by which the immune response is stimulated 
by vaccination (IS) and the resulting measured immune response dynamics (ID). To move IS/ID 
modelling forward, existing datasets and further data on vaccine allometry and dose-
dependent dynamics need to be generated and collate, requiring a collaborative environment 
with input from academia, industry, regulators, governmental and non-governmental 
agencies to share modelling expertise, and connect modellers to vaccine data. 
 
 
  
Importance of vaccine dose-response curve shape 
 
Vaccines are a key public health discovery and are one of the most cost-efficient interventions 
available in medicine [1]. Finding optimal vaccine dose amounts (hereafter dose), as well as 
identifying appropriate regimens, are key factors in reaching maximal vaccine efficacy at the 
requisite safety level. However, taking a vaccine from discovery to licensure can cost in the 
range of US$0.8 billion [2]. With these enormous costs, there is an intense pressure to make 
well-informed decisions at each stage of the development process. However, the current use 
of antiquated methods, may lead to sub-optimal dosing decisions. 
 
Recent conditions including increased demand, resource limitation and cost have led the 
World Health Organization (WHO) to conduct retrospective dose ranging studies where the 
immunogenicity and/or efficacy of fractional doses (of full licensed doses) were tested. For 
diseases such as yellow fever [3, 4] , meningitis [5] and malaria [6], assuming the same 
administration route, fractional doses were found to be equivalent to, or in some cases more 
immunogenic than  full licensed doses. Retrospective dose ranging studies have led to a policy 
change in yellow fever vaccines, where the WHO now recommends that a fractional 1/5th 
(volume) yellow fever vaccine dose may be used in outbreak situations where supply is low 
[7]. This fractional dose has been administered to five million persons in Brazil to date [8]. 
These studies highlight an important question; if smaller doses are optimal with respect to 
immunogenicity (and participant exposure to pathogen) as compared to a large licensed dose, 
then why were they either missed or not initially selected for licensure during development? 
 
Another example of sub-optimal dosing decisions is evident in the development of the novel 
subunit TB vaccines, H-series, which are currently in phase 1/2a clinical trials. Development 
of the H-series vaccine has benefitted from robust dose escalation studies. The dose ranging 
data from small animal studies suggested that the immunogenicity of the vaccine was highest 
at middle doses (0.05 to 1 µg vaccine antigen) and then decreased with the higher doses (5 
and 15 µg vaccine antigen) [9-11]. This phenomenon creates a peaked or n-shaped dose-
response curve, commonly referred to as the goldilocks effect [12]. Clinical testing showed a 
similar peaked dose-response curve; smaller doses (5, 15 µg vaccine antigen) were more 
immunogenic than higher doses (50, 150 µg) [13, 14]. However, in the early phase 1/2 clinical 
trials, a single dose of 50 µg vaccine antigen was chosen [15-17]. Thus, despite the pre-clinical 
dose-response data showing lower doses were more immunogenic, the lower end of the 
dose-response curve in humans has not been fully explored and higher doses were selected.  
 
Peaked dose-response curves are not unique to TB vaccines; similar dose-response curves 
have also been seen in adenovirus (Ad35) [18, 19], HIV [20], malaria [6] and influenza [21] 
vaccines. This is contrary to a long-standing vaccine development assumption that the 
relationship between dose and host response is saturating (sigmoidal) [22]; i.e. there is a 
minimum vaccine dose that gives no host response, a window of vaccine doses where the 
response rapidly escalates and a plateau above a certain dose threshold. Following this 
assumption, the goal of vaccine development is to then increase dose until a response 
plateaus and assume that it is the highest, safe optimal dose (with some margin of error to 
allow for host variation). In contrast, peaked curves suggest that there is a risk that high, 
suboptimal doses could be progressing to later clinical development stages. Thus, more in-
depth analysis of the shape of the vaccine dose-immune response curve, which has been 
largely ignored to date, is essential to understanding how to select optimal dose.  
 
Difficulties with current vaccine dose-finding approaches 
 
It is likely that in many cases, sub-optimal vaccines doses have been selected. Surprisingly, 
the definitive text on vaccine development does not include strategies for dose finding [23] 
and there is limited regulatory guidance on dose-finding methodologies from licensing 
organizations such as the FDA.  
 
Currently, estimates for effective human doses are based on responses in small animal 
models (such as mice and rats) in which large dose ranges are tested over short timeframes. 
Typically,  “low” doses that are used in mice or other small animals are selected and increased 
by half log to one log increments until an assumed maximum plateau in response is met. The 
next step is then to translate vaccine responses from these animal studies to humans, known 
as allometric scaling. Briefly, allometric scaling is the quantifiable relationship between animal 
body size and characteristic, e.g. the physiological relationship between animal size and 
metabolism or life span. In humans, allometric scaling is applied to common PK parameters 
such as volume of distribution, absorption and clearance by using the host’s weight, (e.g. for 
the drug Isoniazid e.g.[24]). Challenges are faced when applying vaccine dose allometric 
scaling between species, as the immunological relationships are still not well characterized, 
and fraught with issues of not only scale, but physiological differences between species. For 
example, assumed vaccine dose allometric scaling factors between mice and human vary over 
large ranges from 5-20 for HPV vaccines [25, 26] to 0.5-100 for TB vaccines [27-30]. There is 
a significant gap and lack of research into how vaccine doses translate across species and 
current vaccine dose allometric scaling assumptions are commonly not explicitly disclosed. 
 
Additional technical issue are present with vaccine development studies. First,  an inability to 
dilute vaccines to small enough dose, lack of more than one dose formulation starting 
material, and/or assay variation could also be contributing to under-researched dose-
response curves. For example, a trial of a gp120 vaccine for HIV-1 infection in humans with 
different adjuvants, revealed that the surrogate response (which in this case was binding and 
homologous virus neutralization) at a dose of 30 μg formulated with QS-21 was equivalent to 
that of 300 μg of the same vaccine in alum. A further study with 0.5, 3, and 30 μg of the 
vaccine in the adjuvant, QS-21, revealed no decrease in response. Thus, neither the lower 
bound nor the shape of the dose-response curve has been established, primarily due to an 
inability to further accurately dilute this vaccine. On the other end of the dose-response 
curve, accurate assessment can be limited by an inability to achieve sufficient concentrations 
to reach a maximal dose as defined by immunologic, clinical, or safety parameters.  
 
Second, a common barrier to efficient vaccine development is the potential lack of biological 
marker of protection, or biomarker. Without such a biomarker, validation of early decisions 
on developmental variables, such as dose, are unattainable. However, vaccines are often 
progressed through to clinical trials based on a hypothetical surrogate of protection - only 
after efficacy has been confirmed can a chosen surrogate  be properly validated [31]. 
 
In summary, it is likely that the current empirical methods used in vaccine dose finding are 
leading to sub-optimal vaccines dose selections. Thus, to identify an optimal combination of 
developmental variables with current approaches (e.g. dose, dose regimen, vaccine 
composition (adjuvant dose)) will require a large, expensive multi-dimensional factorial 
design trial. As a result, vaccine doses are moving forward without extensive evaluation, 
which is often due to insufficient funding, developmental time pressures and lack of a clear 
optimized pipeline. Can a more effective and systematic identification protocol for optimal 
vaccine dosing be achieved?  
 
Immunostimulation (IS) /Immunodynamic (ID) modelling: Mathematical modelling for 
improved vaccine dose decision making 
 
The world of drug development has faced similar drug-dosing questions, yet is far more 
advanced in the use of systematic methods for dose optimization. This can be attributed 
partly to the use of pharmacometrics (or systems pharmacology): mathematical models that 
describe within host drug dynamics. The most commonly models used are 
pharmacokinetic/pharmacodynamic (PK/PD) models that employ mechanistic mathematical 
models to quantify drug concentration dynamics within the host over time (PK) and track drug 
effect and dynamics as drug concentration varies (PD) [32]. Model-Based Drug Development 
(MBDD) is recognized as an efficient tool to accelerate and streamline drug development by 
minimizing developmental time and resources and is regularly used to establish optimal drug 
doses [33]. MBDD has been established for decades in the pharmaceutical industry to 
improve dose selection for small molecule drugs [34] and is often required by regulatory 
agencies in all stages of drug development. As an example, modelling was able to tease 
through the different doses and protocols to derive optimal values for TB drug treatments, 
which previously had never been formally compared [35]. 
 
As yet, there is no such parallel to these methods used for vaccine dosing, which may be due 
to the diversity and complexity of immune responses measured or a lack of appreciation of 
potential quantitative tools. Application of similar methods to those used in drug 
development could lead to better evaluation of vaccine dose-response data derived from 
animals and its translation to humans to potentially improve vaccine development. Vaccine 
development is now in a position (decades later) to borrow from the experiences, expertise 
and technical utilities of MBDD. Consequently, we propose the new field of vaccine 
Immunostimulation/Immunodynamic (IS/ID) modelling as a method to improve vaccine dose 
decision-making and ultimately vaccine discovery. Analogous to PK/PD modelling, IS/ID 
modelling applies mathematical models to describe the underlying mechanisms, the immune 
response stimulation (IS) that produces measured immune response dynamics following 
vaccination (ID).  
 
The application of IS/ID modelling to accelerate vaccine development could provide the 
following benefits. Firstly, a mathematical and computational modelling framework would 
have the capability to more effectively evaluate in silico greater combinations of vaccine trial 
design variables and narrow the design space before trials ever begin. Secondly, the 
incorporation of mathematical modelling into pre-clinical vaccine development could 
eventually result in a reduction in laboratory animals by replacing empirical experimentation 
with in silico simulation that optimizes the selection of doses and number of animals [36]. 
Similarly, the application of IS/ID modelling to clinical vaccine trial design could also reduce 
trial sample size and thus the total human exposure to investigational agents. Finally, the 
immune response required for protection against a disease relies on complex interactions 
that behave nonlinearly over time and across multiple biological scales (e.g. molecular to 
cellular to whole systems). IS/ID models will allow us to quantify this complexity to obtain 
meaningful biological predictions while retaining model identifiability.  
 
IS/ID modelling vaccine development is limited only by the issues already facing the vaccine 
development world. Decisions on vaccine dose and dose regimen are currently being made 
regardless of a developer’s knowledge on dose allometry, an established correlate of 
protection, or extensive immune response data. Our goal with IS/ID modelling is not to discuss 
the correct vaccine induced immune measure, but to suggest a more systematic framework 
to inform key vaccine dose decisions based on a chosen surrogate and applying established 
methods currently used in drug development. Consequently, we would like to highlight  that 
application of IS/ID modelling to vaccine development is not limited to a particular disease, 
type of vaccine or induction of a specific type of immune response and is also adaptable to 
vaccine requirements and available data. 
 
IS/ID modelling implementation 
 
The generalized steps (for any vaccine) to integrate modelling into dose finding are outlined 
below, (a scheme of the steps is in Figure 1): 
 
1. A wide range of doses of a new immunogenic vaccine are tested in small animal 
models to find minimum and maximum doses that provide the bounds of the dose-
response curve (note adjuvant dose could/should also be varied). The dose range, 
although wide, can be based on historical work of similar vaccines. 
2. IS/ID mathematical modelling is applied to estimate the parameters that describe the 
underlying dynamics of the initial animal-derived dose-response relationship. Optimal 
experimental design is then generated to yield the maximum information on the dose-
response curve (with a pre-specified confidence interval), given limitations on animal 
numbers, ability to achieve  desired concentrations of the product, and cost.  
3. The IS/ID model is calibrated to human response data on limited doses and using 
allometric dose scaling assumptions (or tested in a human-immune response 
computational model [37]), the animal IS/ID model parameters are used to predict the 
theoretical human dose-response relationship and can be tested in the human-
immune response computational model. 
4. As in step 1, a selection of doses are chosen to define an approximate shape and the 
confidence bounds of the human dose-response curve based on the theoretical 
prediction in steps 1-3.  
5. These data are then fed back into the model to gain understanding of the confidence 
intervals around the chosen doses. As further human data are collected, the IS/ID 
model is refined and used to hone in on best dose and it’s confidence interval. 
 
Current IS/ID modelling  
 
The first steps to include IS/ID modelling into vaccine development are under way. We 
conducted an intensive animal vaccine multi-dose study of a candidate TB vaccine (presently 
in phase 2) designed by Rhodes et. al. to  specifically  generate data for dose-response 
identification using translational IS/ID methods. IS/ID modelling was applied to determine the 
dose-response curve and showed a definitive n-shape for multiple times points after 
vaccination [11]. This strongly suggests that the predicted best dose is likely to be lower than 
previously investigated [11].  Preliminary work has also been conducted to simulate further 
responses (based on these empirical data) to obtain optimal dosing cohorts and narrow the 
confidence interval around predicted best dose. In addition, current work underway develops 
an IS/ID mechanistic model of the TB vaccine dose-dependent induction of memory, effector, 
and regulatory T cell subsets and, using well established model parameter estimation 
methods employed in population PK/PD modelling (i.e. nonlinear mixed effects modelling), 
translated the dose-response curve from mice to humans ([38] and paper in submission). The 
results of this work suggest a lower dose than has been used in phase 1 trials in humans may 
be the most immunogenic. Importantly, this model prediction has since been supported by 
large phase 2 trial. 
 
Future work to inform IS/ID vaccine dose modelling 
 
In order to apply IS/ID modelling effectively to vaccine development, further datasets are 
required. For example, a thorough investigation into vaccine allometry, which is vital to scale 
vaccine dose across species, should be undertaken. Additionally, more extensive studies on 
immune system dynamics by dose should be introduced early on to pre-clinical investigations. 
In drug development, modelers use all available (relevant and standardized) data to refine 
understanding of PK/PD findings throughout product development. To maximize information 
on vaccine allometric scaling information and model parameterization across vaccines in the 
same way, we recommend the creation and curation of large shared dose-response data 
platforms through large-scale collaborative efforts with multinational pharmaceutical 
companies.  
 
Second, a collaborative group of interested parties from academia, biotech, large vaccine 
manufacturers, regulators, governmental and non-governmental agencies must be 
established to aid communication, data access and development of methodology. The first 
meeting of such a group of individuals occurred in May 2015 at the headquarters of TB vaccine 
developers Aeras (Rockville, MD), where a multidisciplinary team met to discuss the current 
state of vaccine dose finding and the potential for mathematical modelling to assist in this 
arena. Creating such a network, would provide links between existing modelling consortia 
such as the TB, HIV, Malaria, NCD modelling consortia and International Society of 
Pharmacometrics to facilitate access to modelling expertise. Incentives such as open access 
to large historical data packages, and a commitment by vaccine developers, should be put in 
place to encourage modelers with experience in drug dosing and immune response modeling 
to move to vaccine development, which can have a potentially greater impact on human 
health. We believe that vaccine regulatory bodies also lack critical evaluations of vaccine 
product dose selection, and that agencies such as FDA or EMA should encourage modelers to 
move from the drug development focus into vaccine development. Thus, the motivation and 
investments must come in both a bottom-up and top-down fashion. 
 
Finally, and most critically, we encourage the NIH and other vaccine funding agencies to 
consider head to head studies in which conventional methods for selecting vaccine do are 
used in parallel with the outlined modelling techniques, to better understand the impact on 
speed of development, number of participants exposed and cost of vaccine design. Only then 
can the true value of the endeavor be assessed.  
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Figure 1. Schema depicting the steps required to incorporate immunostimulation (IS) /immunodynamic (ID) modeling into vaccine development. [Graphics included credited to: 
https://thenounproject.com].
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